Objectives To explore pain-specific, general health-related quality of life (HRQoL), and
safety outcomes of chronic pain patients prescribed cannabis-based medicinal products …

Background Though chronic pain is widespread, affecting about one-fifth of the world's
population, its impacts are disproportionately felt across the population according to …

Cannabis‐based medicinal products (CBMPs) are an emerging therapeutic option in the
management of primary chronic pain, using the role of the endocannabinoid system in …

Pain is one of the most burdensome symptoms in people with cancer, and opioid analgesics
are considered the mainstay of cancer pain management. For this review, the authors …

Background There is well-established evidence linking adverse childhood experiences
(ACEs) and chronic pain in adulthood. It is less clear how ACE exposure might influence the …

Objectives In 2019–2020, four national recommendations were published in the United
Kingdom to encourage use of low carbon inhalers. This study aimed to investigate whether …

Background Opioid and gabapentinoid prescribing has increased substantially in recent
years despite having limited effectiveness in treating chronic primary pain. This is …

Background Gabapentinoids have been prescribed off-label for almost all types of pain. The
geographic variation in the use of gabapentinoids as analgesics remains unknown …

The importance of non-fatal overdose in reducing drug related deaths characteristics of non-fatal
overdoses and associated risk factors in patients attending a specialist community-based …

In 2020, the number of drug-related deaths (DRDs) in Scotland reached a record high of
1339 [1]. This is the 7th year in a row that deaths from drug misuse have reached record …